<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01488409</url>
  </required_header>
  <id_info>
    <org_study_id>2011-P-000175</org_study_id>
    <nct_id>NCT01488409</nct_id>
  </id_info>
  <brief_title>Effects of Acipimox on Mitochondrial Function in Obesity</brief_title>
  <official_title>The Effects of Short Term Acipimox Treatment on Skeletal Muscle Phosphocreatine Recovery in Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to examine whether a medication called acipimox can improve your
      body's mitochondria. Mitochondria are the &quot;power house&quot; of the cell and make energy for your
      body.

      Obesity is associated with increased risk for developing diabetes. However, the investigators
      do not know how obesity leads to diabetes. Previous studies have shown levels of fat in the
      blood (free fatty acids or FFA) are higher in obesity, and elevated FFA can affect how our
      body uses glucose and responds to insulin. Recent studies have shown that changes in
      mitochondria may be involved in the development of diabetes and may be affected by FFA. The
      investigators propose to improve the function of mitochondria in obese people with
      pre-diabetes by treating with acipimox, a medication which decreases FFA. The investigators
      will use state of the art techniques to evaluate the mitochondria, including a new magnetic
      resonance imaging (MRI) technique to measure function of mitochondria in muscle.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Phosphocreatine Recovery (ViPCr) at 6-months</measure>
    <time_frame>Change from Baseline to 6-months Visit</time_frame>
    <description>The rate of recovery of phosphocreatine concentration after depletion by exercise is considered a measurement of mitochondrial function. Change in phosphocreatine recovery from baseline to 6 months will therefore give a measurement of change in mitochondrial function. ViPCR is given -- a higher value indicates better mitochondrial function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Insulin Sensitivity at 6-months</measure>
    <time_frame>Change from Baseline to 6-months visit</time_frame>
    <description>Change in insulin resistance assessed by hyperinsulinemic-euglycemic clamp study at Baseline and at 6-months. Change in insulin-stimulated glucose uptake (M) during 40 mU/m2/min insulin clamp is given.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mitochondrial Density at 6 Months</measure>
    <time_frame>Change from Baseline to 6-months</time_frame>
    <description>Muscle tissue obtained from biopsy will be used to assess mitochondrial number and morphology by microscopes at Baseline and at 6-months. The change in mitochondrial density from 6 months to baseline is given.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Intramyocellular Lipid Content at 6-months</measure>
    <time_frame>Change from Baseline to 6-months</time_frame>
    <description>Change in tibialis intramyocellular lipid (IMCL) normalized to creatinine is given.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lipid Profile at 6-months</measure>
    <time_frame>Change from Baseline to 6-months</time_frame>
    <description>Change in direct low density lipoprotein (LDL) cholesterol is given</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Abdominal Obesity</condition>
  <condition>Insulin Resistance</condition>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Acipimox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with the study drug Acipimox</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with Placebo control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acipimox</intervention_name>
    <description>250 mg by mouth (PO) three times daily</description>
    <arm_group_label>Acipimox</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0 mg by mouth (PO) three times daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women age 18-55 years old

          2. Body Mass Index (BMI) ≥ 30 kg/m2

          3. Waist circumference ≥ 102 cm in men and ≥ 88 cm in women

          4. Hypertriglyceridemia defined as triglycerides ≥ 150 mg/dl OR Insulin resistance
             defined as elevated fasting glucose (≥ 100 mg/dl but &lt;125 mg/dl) or hyperinsulinemia
             defined as fasting serum insulin ≥ 10 uU/ml.

        Exclusion Criteria:

          1. Subjects on any hormonal treatment including estrogen, hormone replacement therapy,
             oral contraceptives, testosterone, glucocorticoids, anabolic steroids, GH, GH
             releasing hormone or Insulin like growth factor (IGF)-1 within 3months of enrollment.

          2. Subjects who have a known history of diabetes, using any anti-diabetic drugs, or
             fasting blood glucose of ≥ 125 mg/dl.

          3. Use of cholesterol lowering medication including niacin or fish oil.

          4. Changes in anti-hypertensive regimen within 3months of screening.

          5. Chronic illness including HIV, anemia (Hgb &lt;12 g/dL), chronic kidney disease
             (Creatinine &gt; 2 mg/dL), or liver disease (SGOT &gt; 2.5 x upper limit normal).

          6. Use of Aspirin, Clopidogrel (Plavix), Warfarin (Coumadin) or other anti-coagulants

          7. History of or active peptic ulcer disease

          8. History of any recent cardiovascular event including myocardial infarction (MI; heart
             attack), cerebral vascular accident (CVA; or stroke) or transient ischemic attack
             (TIA; or mini-stroke) within 3 months of screening visit, unstable angina pectoris,
             oxygen-dependent severe pulmonary disease

          9. Subjects with contraindication for an MRI study including any significant metal in
             their body including surgical clippings, or pacemakers and known claustrophobia.

         10. History of recent alcohol or substance abuse (&lt; 1 year)

         11. Positive pregnancy test or lactating females

         12. Women of child-bearing potential not currently using non-hormonal birth control
             methods including barrier methods (intra-uterine device or IUD, condoms, diaphragms)
             or abstinence

         13. Subject is currently enrolled in another investigational device or drug trial(s), or
             subject has received other investigational agent(s) within 28 days of baseline visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Grinspoon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2011</study_first_submitted>
  <study_first_submitted_qc>December 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2011</study_first_posted>
  <results_first_submitted>January 4, 2016</results_first_submitted>
  <results_first_submitted_qc>January 4, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 3, 2016</results_first_posted>
  <last_update_submitted>February 2, 2016</last_update_submitted>
  <last_update_submitted_qc>February 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Steven K. Grinspoon, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
    <mesh_term>Obesity, Abdominal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acipimox</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acipimox</title>
          <description>Treatment with the study drug Acipimox
Acipimox: 250 mg by mouth (PO) three times daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Treatment with Placebo control.
Placebo: 0 mg by mouth (PO) three times daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acipimox</title>
          <description>Treatment with the study drug Acipimox
Acipimox: 250 mg by mouth (PO) three times daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Treatment with Placebo control.
Placebo: 0 mg by mouth (PO) three times daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="5"/>
                    <measurement group_id="B2" value="45" spread="7"/>
                    <measurement group_id="B3" value="46" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Phosphocreatine Recovery (ViPCr) at 6-months</title>
        <description>The rate of recovery of phosphocreatine concentration after depletion by exercise is considered a measurement of mitochondrial function. Change in phosphocreatine recovery from baseline to 6 months will therefore give a measurement of change in mitochondrial function. ViPCR is given -- a higher value indicates better mitochondrial function.</description>
        <time_frame>Change from Baseline to 6-months Visit</time_frame>
        <population>all available data used</population>
        <group_list>
          <group group_id="O1">
            <title>Acipimox</title>
            <description>Treatment with the study drug Acipimox
Acipimox: 250 mg by mouth (PO) three times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Treatment with Placebo control.
Placebo: 0 mg by mouth (PO) three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Phosphocreatine Recovery (ViPCr) at 6-months</title>
          <description>The rate of recovery of phosphocreatine concentration after depletion by exercise is considered a measurement of mitochondrial function. Change in phosphocreatine recovery from baseline to 6 months will therefore give a measurement of change in mitochondrial function. ViPCR is given -- a higher value indicates better mitochondrial function.</description>
          <population>all available data used</population>
          <units>mM/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="9.6"/>
                    <measurement group_id="O2" value="1.6" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Insulin Sensitivity at 6-months</title>
        <description>Change in insulin resistance assessed by hyperinsulinemic-euglycemic clamp study at Baseline and at 6-months. Change in insulin-stimulated glucose uptake (M) during 40 mU/m2/min insulin clamp is given.</description>
        <time_frame>Change from Baseline to 6-months visit</time_frame>
        <population>all available data used</population>
        <group_list>
          <group group_id="O1">
            <title>Acipimox</title>
            <description>Treatment with the study drug Acipimox
Acipimox: 250 mg by mouth (PO) three times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Treatment with Placebo control.
Placebo: 0 mg by mouth (PO) three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Insulin Sensitivity at 6-months</title>
          <description>Change in insulin resistance assessed by hyperinsulinemic-euglycemic clamp study at Baseline and at 6-months. Change in insulin-stimulated glucose uptake (M) during 40 mU/m2/min insulin clamp is given.</description>
          <population>all available data used</population>
          <units>mg/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.9"/>
                    <measurement group_id="O2" value="0.2" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.85</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mitochondrial Density at 6 Months</title>
        <description>Muscle tissue obtained from biopsy will be used to assess mitochondrial number and morphology by microscopes at Baseline and at 6-months. The change in mitochondrial density from 6 months to baseline is given.</description>
        <time_frame>Change from Baseline to 6-months</time_frame>
        <population>all available data used</population>
        <group_list>
          <group group_id="O1">
            <title>Acipimox</title>
            <description>Treatment with the study drug Acipimox
Acipimox: 250 mg by mouth (PO) three times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Treatment with Placebo control.
Placebo: 0 mg by mouth (PO) three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mitochondrial Density at 6 Months</title>
          <description>Muscle tissue obtained from biopsy will be used to assess mitochondrial number and morphology by microscopes at Baseline and at 6-months. The change in mitochondrial density from 6 months to baseline is given.</description>
          <population>all available data used</population>
          <units>percentage of total muscle fiber area</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.3"/>
                    <measurement group_id="O2" value="0" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.52</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Intramyocellular Lipid Content at 6-months</title>
        <description>Change in tibialis intramyocellular lipid (IMCL) normalized to creatinine is given.</description>
        <time_frame>Change from Baseline to 6-months</time_frame>
        <population>all available data used</population>
        <group_list>
          <group group_id="O1">
            <title>Acipimox</title>
            <description>Treatment with the study drug Acipimox
Acipimox: 250 mg by mouth (PO) three times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Treatment with Placebo control.
Placebo: 0 mg by mouth (PO) three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Intramyocellular Lipid Content at 6-months</title>
          <description>Change in tibialis intramyocellular lipid (IMCL) normalized to creatinine is given.</description>
          <population>all available data used</population>
          <units>ratio of IMCL peak to Creatinine peak</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="3.0"/>
                    <measurement group_id="O2" value="0.0" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.79</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lipid Profile at 6-months</title>
        <description>Change in direct low density lipoprotein (LDL) cholesterol is given</description>
        <time_frame>Change from Baseline to 6-months</time_frame>
        <population>all available data used</population>
        <group_list>
          <group group_id="O1">
            <title>Acipimox</title>
            <description>Treatment with the study drug Acipimox
Acipimox: 250 mg by mouth (PO) three times daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Treatment with Placebo control.
Placebo: 0 mg by mouth (PO) three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lipid Profile at 6-months</title>
          <description>Change in direct low density lipoprotein (LDL) cholesterol is given</description>
          <population>all available data used</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19" spread="26"/>
                    <measurement group_id="O2" value="6" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Acipimox</title>
          <description>Treatment with the study drug Acipimox
Acipimox: 250 mg by mouth (PO) three times daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Treatment with Placebo control.
Placebo: 0 mg by mouth (PO) three times daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>SNOMED CT</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>abdominal bloating</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>gastroesophageal reflux</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>loss of appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>joint pain and swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>pain following biopsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>bleeding following biopsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steven K. Grinspoon</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-9109</phone>
      <email>sgrinspoon@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

